0
Frequency Therapeutics, Inc. Banner Image

Frequency Therapeutics, Inc. has reached its limit for free report views

Work for Frequency Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Frequency Therapeutics, Inc.

  • Ticker FREQ
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Frequency Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Woburn, Massachusetts
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerateMore auditory hair cells to restore hearing function. In an FX-322 Phase 1/2 study, statistically significant and clinically meaningful improvements in key measures of hearing function in patients with sensorineural hearing loss were observed. FX-322 is being evaluated in an ongoing Phase 2a clinical study in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.
Frequency Therapeutics, Inc.

Most Recent Annual Report

Frequency Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Frequency Therapeutics, Inc. has reached its limit for free report views.